- Home
- RRR vs CPRX Comparison
RRR vs CPRX Comparison
Compare RRR & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | CPRX |
|---|---|---|
| Founded | 1976 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | RRR | CPRX |
|---|---|---|
| Price | $57.12 | $22.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $66.46 | $35.00 |
| AVG Volume (30 Days) | 746.6K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | 23.32 | ★ 28.24 |
| EPS | ★ 3.12 | 1.68 |
| Revenue | ★ $2,011,483,000.00 | $119,072,803.00 |
| Revenue This Year | $3.26 | $8.00 |
| Revenue Next Year | $4.48 | $9.77 |
| P/E Ratio | $19.20 | ★ $13.28 |
| Revenue Growth | 3.74 | ★ 16.39 |
| 52 Week Low | $35.09 | $19.05 |
| 52 Week High | $68.99 | $26.56 |
Technical Indicators
Market Signals| Indicator | RRR | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 38.69 |
| Support Level | $55.56 | $22.25 |
| Resistance Level | $61.64 | $24.94 |
| Average True Range (ATR) | 2.02 | 0.69 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 26.59 | 12.84 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.